Literature DB >> 2400810

The t(1;14)(p34;q11) is nonrandom and restricted to T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study.

A J Carroll1, W M Crist, M P Link, M D Amylon, D J Pullen, A H Ragab, G R Buchanan, R S Wimmer, T J Vietti.   

Abstract

We report the nonrandom occurrence, frequency, and degree of immunophenotype association of the t(1;14)(p34;q11) in children with acute lymphoblastic leukemia (ALL). This chromosomal abnormality occurred in leukemia cells from 5 of 1,630 (0.3%) consecutive children with newly diagnosed ALL who were entered on a single Pediatric Oncology Group classification study (POG 8600) between January 1986 and February 1989. The frequency of the t(1;14) was 3% (5 of 168 cases) in children with T-cell ALL. All five cases had pseudodiploid karyotypes, and in 3 cases the t(1;14) was accompanied by a deletion of the long arm of chromosome 6. This translocation is of special interest because the breakpoint on chromosome 14 in band q11 corresponds to the assigned locus of the T-cell receptor alpha/delta chain gene. All five of our patients and three cases reported previously have had T-cell ALL. These findings, considered together, suggest that this translocation is specific for T-cell ALL and that a gene in the 1p34 region may play an important role in malignant transformation of thymocytes.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2400810

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  21 in total

1.  Enhancer-binding activity of the tal-1 oncoprotein in association with the E47/E12 helix-loop-helix proteins.

Authors:  H L Hsu; J T Cheng; Q Chen; R Baer
Journal:  Mol Cell Biol       Date:  1991-06       Impact factor: 4.272

2.  An scl gene product lacking the transactivation domain induces bony abnormalities and cooperates with LMO1 to generate T-cell malignancies in transgenic mice.

Authors:  P D Aplan; C A Jones; D S Chervinsky; X Zhao; M Ellsworth; C Wu; E A McGuire; K W Gross
Journal:  EMBO J       Date:  1997-05-01       Impact factor: 11.598

3.  The LIM-only protein Lmo2 is a bridging molecule assembling an erythroid, DNA-binding complex which includes the TAL1, E47, GATA-1 and Ldb1/NLI proteins.

Authors:  I A Wadman; H Osada; G G Grütz; A D Agulnick; H Westphal; A Forster; T H Rabbitts
Journal:  EMBO J       Date:  1997-06-02       Impact factor: 11.598

4.  Tal-1 induces T cell acute lymphoblastic leukemia accelerated by casein kinase IIalpha.

Authors:  M A Kelliher; D C Seldin; P Leder
Journal:  EMBO J       Date:  1996-10-01       Impact factor: 11.598

Review 5.  Genomic Alterations of Non-Coding Regions Underlie Human Cancer: Lessons from T-ALL.

Authors:  Adrian Rivera-Reyes; Katharina E Hayer; Craig H Bassing
Journal:  Trends Mol Med       Date:  2016-10-27       Impact factor: 11.951

6.  Frequency and DNA sequence of tal-1 rearrangement in children with T-cell acute lymphoblastic leukemia.

Authors:  A Borkhardt; R Repp; J Harbott; C Keller; F Berner; J Ritterbach; F Lampert
Journal:  Ann Hematol       Date:  1992-06       Impact factor: 3.673

7.  Rearrangements of the tal-1 locus as clonal markers for T cell acute lymphoblastic leukemia.

Authors:  O G Jonsson; R L Kitchens; R J Baer; G R Buchanan; R G Smith
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

Review 8.  Stem Cell Leukemia: how a TALented actor can go awry on the hematopoietic stage.

Authors:  N C Correia; M-L Arcangeli; F Pflumio; J T Barata
Journal:  Leukemia       Date:  2016-06-13       Impact factor: 11.528

9.  TAL2, a helix-loop-helix gene activated by the (7;9)(q34;q32) translocation in human T-cell leukemia.

Authors:  Y Xia; L Brown; C Y Yang; J T Tsan; M J Siciliano; R Espinosa; M M Le Beau; R J Baer
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-15       Impact factor: 11.205

10.  Molecular involvement of the pvt-1 locus in a gamma/delta T-cell leukemia bearing a variant t(8;14)(q24;q11) translocation.

Authors:  M Kasai; R T Maziarz; K Aoki; E Macintyre; J L Strominger
Journal:  Mol Cell Biol       Date:  1992-10       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.